Algezir Ultra

Algezir Ultra – non-steroidal anti-inflammatory drug (NPVP).

Form of release and structure

Dosage form – tablets, film coated: round, biconvex (275 mg) or oblong, biconvex, with the rounded ends, with risky (550 mg), blue color; on cross section 2 layers, internal – white or white-yellowish color are visible (on 5, 10, 12 or 15 pieces in blister strip packagings, in a pack of cardboard 1, 2, 3, 5, 6 or 10 packagings).

Contains in 1 tablet:

• Active ingredient: sodium Naproxenum – 275 or 550 mg;
• Additional components: silicon dioxide colloid (aerosil), коповидон, sugar milk (lactose), macrogoal 6000, cellulose microcrystallic, gipromelloz (gidroksipropilmetiltsellyuloz), talc, titanium dioxide, calcium stearate, dye diamond blue.

Indications to use

• Feverish syndrome at infectious and "catarrhal" diseases;
• Pain syndrome of weak or moderate degree of manifestation: a posttraumatic pain syndrome with an inflammation (stretchings and bruises), postoperative pain (in maxillofacial surgery, orthopedics, traumatology, gynecology), a headache, a dentagra, migraine, a mialgiya, an ossalgiya, a lumbar ishialgia, neuralgia, an adnexitis, альгодисменорея;
• Musculoskeletal system diseases: psoriasis, rhematoid, gouty and juvenile chronic arthritis, rheumatic defeat of soft tissues, Bekhterev's disease (an ankylosing spondylarthritis), a bursitis, a tendovaginitis, an osteoarthrosis of peripheral joints and a backbone, including with a radicular syndrome;
• Infectious and inflammatory diseases of ENT organs with the expressed pain syndrome: otitis, tonsillitis, pharyngitis (as a part of complex therapy).

Tablets Algezir Ultra apply to symptomatic therapy (decrease in the increased body temperature, reduction of pain and an inflammation) and does not influence progressing of a disease.

Contraindications

Absolute:

• Oppression of a marrowy hemopoiesis;
• Disturbance of a hemostasis, cerebrovascular or other bleedings;
• The expressed renal failure (the clearance of creatinine is less than 20 ml/minute);
• The period after performing aortocoronary shunting;
• Exacerbation of an inflammatory disease of intestines (nonspecific ulcer colitis, disease Krone);
• Active gastrointestinal bleeding, erosive and ulcer changes of a mucous membrane of a stomach or 12-perstny gut;
• Anamnestic data on an attack of a bronkhoobstruktion, rhinitis, small tortoiseshell after reception of any NPVP, including acetylsalicylic acid;
• Children's and teenage age up to 15 years;
• Pregnancy and lactation;
• Hypersensitivity to drug components.

Relative (Algezir Ultra take with caution):

• Clearance of creatinine from 20 to 60 ml/minute;
• Diabetes mellitus;
• Дислипидемия / lipidemia;
• Cerebrovascular diseases;
• Coronary heart disease;
• Heavy somatopathies;
• Diseases of peripheral arteries;
• Chronic heart failure;
• Smoking;
• Frequent alcohol intake;
• Existence of an infection of Helicobacter pylori;
• Digestive tract cankers in the anamnesis;
• Advanced age;
• Prolonged treatment using NPVP;
• Concomitant use of selective serotonin reuptake inhibitors (including a tsitaloprama, a paroksetina, fluoxetine, sertraline), anticoagulants (for example, warfarin), peroral glucocorticosteroids (for example, Prednisolonum), antiagregant (including klopidogret, acetylsalicylic acid).

Route of administration and dosage

Algezir Ultra it is necessary to accept inside during food: to swallow of tablets entirely and to wash down with enough liquid.

The recommended doses:

• Pain syndrome: 550-1100 mg, at the diseases which are followed by very severe pains, but on condition of lack of anamnestic data on digestive tract diseases, are possible increase in a daily dose up to 1650 mg, however duration of such treatment should not exceed 2 weeks;
• The increased body temperature: the first dose – 550 mg, further each 6-8 hours – on 275 mg;
• Migraine: at a pain syndrome – on 550 mg 2 times a day if within 4-6 weeks intensity, duration and frequency of attacks of migraine do not decrease, drug should be cancelled; at the first signs of a migrenozny attack it is recommended to accept 825 mg, if necessary in 30 minutes – 275-550 more mg;
• Gynecologic pains (альгодисменорея, an adnexitis, pain after introduction of an intrauterine spiral, etc.): an initial dose – 550 mg, further each 6-8 hours – on 275 mg;
• Bad attack of gout: an initial dose – 825 mg, in 8 hours – 550 mg, further each 8 hours – on 275 mg before the termination of an attack;
• Rheumatic diseases: on 550-1100 mg 2 times a day (in the morning and in the evening) depending on a clinical situation.

The usual daily dose makes 550-1100 mg in 2 receptions.

To patients at whom pain is the main symptom, the patients transferred on Algezir Ultra from high doses of other NPVP and also at the expressed night pain and/or morning constraint the recommended initial daily dose makes 825-1650 mg.

Side effects

• From the alimentary system: stomacaces, a diarrhea/lock, a melena, discomfort in epigastriums, nausea, an abdominal pain, vomiting, vomiting with blood, bleeding and perforation of digestive tract, the abnormal liver function, increase in activity of liver enzymes, gastropathies connected with reception of NPVP (defeat of antral department of a stomach in the form of ulcers, erosion, hemorrhages, an erythema of a mucous membrane), jaundice, hepatitis;
• From cardiovascular system: short wind, hypostases, heartbeat, vasculitis, congestive heart failure;
• From urinogenital system: nephrotic syndrome, hamaturia, renal papillary necrosis, renal failure, intersticial nephrite, glomerulonephritis, disturbances of a menstrual cycle;
• From the central nervous system: difficulty of concentration of attention, sleep disorder, drowsiness, headache, dizziness, sleeplessness, muscular weakness, delay of speed of response, mialgiya, aseptic meningitis, indisposition, cognitive dysfunction, depression;
• From the hemopoietic bodies: hemolitic anemia, thrombocytopenia, leukopenia, aplastic anemia, granulocytopenia, eosinophilia;
• From respiratory system: eosinophilic pneumonia;
• From sense bodys: vision disorder, decrease in hearing, sonitus;
• From integuments: ecchymomas, an itch, the increased perspiration, photodermatoses, an alopecia, a Werlhof's disease;
• Allergic reactions: urticaria, skin rash, Stephens-Johnson's syndrome, multiformny exudative erythema, epidermal toxic necrolysis (Lyell's disease), Quincke's disease;
• Other reactions: hypoglycemia, hyperglycemia, hyperthermia, thirst.

Special instructions

In order to avoid development of undesirable reactions from digestive tract Algezir Ultra in a minimal effective dose minimum possible short course is recommended to accept.

If fever and/or pain remain or amplify, it is necessary to see a doctor.

At patients with a renal failure during treatment by Naproxenum it is necessary to control clearance of creatinine. If this level is lower than 20 ml/minute, it is not recommended to accept drug.

To patients with hypersensitivity to other analgetics, disturbance of coagulability of blood and bronchial asthma before Algezir Ultr's use it is necessary to consult with the doctor.

Patients who undergo therapy by anticoagulants need to consider that Naproxenum can increase a bleeding time.

Concentration of untied Naproxenum increases at cirrhosis (including chronic alcoholic) therefore such patients are recommended to accept lower doses. The dose decline is necessary also for people of advanced age.

Without appointment of the doctor Algezir Ultra it is impossible to accept along with other analgeziruyushchy and anti-inflammatory drugs.

Drug is cancelled in 48 hours prior to surgical intervention, carrying out the analysis on definition of 17 ketosteroids and concentration in urine of 5-xyindole acetic acid.

Patients who adhere to a diet with salt consumption restriction should consider that each tablet contains about 25 mg of sodium.

Medicinal interaction

Algezir Ultra do not accept along with other NPVS as the risk of development of side effects increases.

Magnesium - and aluminum-bearing antacids reduce absorption of Naproxenum, пробенецид increases its concentration in a blood plasma.

At the combined use with cyclosporine the risk of development of a renal failure increases.

At simultaneous use of drugs which substantially contact proteins of plasma (for example, anticoagulants, dipheninum, Phenytoinum) strengthening of their action or overdose is possible.

Naproxenum can inhibit a natriuretic effect of furosemide, reduce hypotensive effect of beta adrenoblockers (including propranolol), and also to increase risk of development of a renal failure owing to use of inhibitors of an angiotensin-converting enzyme.

Naproxenum promotes increase in concentration of lithium in plasma, and also slows down excretion of streptocides, Phenytoinum and a methotrexate because of what increases probability of development of their toxic action.

Myelotoxic means strengthen manifestations of a gematotoksichnost of Algezir Ultr.

Terms and storage conditions

To store in the unavailable to children, protected from light and moisture place, at a temperature up to 25 °C.

Period of validity – 2 years.